RhumbLine Advisers
AZN icon

RhumbLine Advisers’s AstraZeneca AZN Stock Holding History

RhumbLine Advisers’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Sell
10,654
-96
-0.9% -$18.1K ﹤0.01% 1929
2026
Q1 		$2.12M Sell
10,750
-2,297
-18% -$443K ﹤0.01% 1820
2025
Q4 		$2.4M Sell
13,047
-341
-3% -$59.8K ﹤0.01% 1763
2025
Q3 		$2.05M Sell
13,388
-1,144
-8% -$173K ﹤0.01% 1900
2025
Q2 		$2.03M Buy
14,532
+461
+3% +$64.6K ﹤0.01% 1880
2025
Q1 		$2.07M Sell
14,071
-491
-3% -$71K ﹤0.01% 1792
2024
Q4 		$1.91M Buy
14,562
+202
+1% +$28.3K ﹤0.01% 1904
2024
Q3 		$2.24M Buy
14,360
+1,293
+10% +$209K ﹤0.01% 1845
2024
Q2 		$2.04M Sell
13,067
-305
-2% -$45.9K ﹤0.01% 1873
2024
Q1 		$1.81M Buy
13,372
+889
+7% +$118K ﹤0.01% 1947
2023
Q4 		$1.68M Buy
12,483
+308
+3% +$40K ﹤0.01% 1996
2023
Q3 		$1.65M Buy
12,175
+438
+4% +$59.8K ﹤0.01% 1951
2023
Q2 		$1.68M Buy
+11,737
New +$1.73M ﹤0.01% 2006
2016
Q3 		– Sell
-13,580
Closed -$820K – 2872
2016
Q2 		$820K Sell
13,580
-150
-1% -$8.71K ﹤0.01% 1906
2016
Q1 		$773K Hold
13,730
– – ﹤0.01% 1959
2015
Q4 		$932K Buy
13,730
+700
+5% +$45.9K ﹤0.01% 1857
2015
Q3 		$829K Hold
13,030
– – ﹤0.01% 1888
2015
Q2 		$830K Sell
13,030
-3,200
-20% -$219K ﹤0.01% 1991
2015
Q1 		$1.11M Sell
16,230
-1,400
-8% -$97.3K ﹤0.01% 1787
2014
Q4 		$1.24M Hold
17,630
– – ﹤0.01% 1664
2014
Q3 		$1.26M Sell
17,630
-500
-3% -$36.6K ﹤0.01% 1607
2014
Q2 		$1.35M Buy
18,130
+600
+3% +$43.4K ﹤0.01% 1640
2014
Q1 		$1.14M Sell
17,530
-100
-0.6% -$6.46K ﹤0.01% 1711
2013
Q4 		$1.05M Buy
17,630
+9,300
+112% +$505K ﹤0.01% 1779
2013
Q3 		$433K Buy
8,330
+2,900
+53% +$146K ﹤0.01% 2310
2013
Q2 		$257K Buy
+5,430
New +$277K ﹤0.01% 2776

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RhumbLine Advisers's AZN Position: Q2 2026 in Review

RhumbLine Advisers reduced its AstraZeneca (AZN) stake by 0.89% in Q2 2026, selling an estimated $18.1K and leaving 10,654 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1929.

RhumbLine Advisers first reported a position in AZN in Q2 2013 and has held it in 26 quarters since. The position peaked at $2.4M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • RhumbLine Advisers held 10,654 shares of AstraZeneca worth $2.02M as of Q2 2026.
  • RhumbLine Advisers sold 96 AstraZeneca shares in Q2 2026, an estimated $18.1K.
  • AstraZeneca made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1929 holding.
  • RhumbLine Advisers first reported a position in AstraZeneca in Q2 2013 and has held it in 26 quarters since.
  • RhumbLine Advisers's AstraZeneca position peaked at $2.4M in Q4 2025.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.